Business
JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited
LONDON--(BUSINESS WIRE)-- JATT Acquisition Corp (NYSE: JATT, JATT.WS and JATT.U) (the "Company"), a publicly-traded special purpose acquisition company,
About this update from Jatt Ii Acquisition Corp
[{"type":"text","content":" LONDON--(BUSINESS WIRE)--\nJATT Acquisition Corp (NYSE: JATT, JATT.WS and JATT.U) (the \"Company\"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class A ordinary shares, public warrants and units from the New York Stock Exchange (“NYSE”) to the Nasdaq Stock Market LLC (“Nasdaq”) in connection with, and upon the closing of, the previously announced business combination (the “Business Combination”) with Zura Bio Limited, a limited company incorporated under the laws of England and Wales (“Zura”).\n\nThe Company expects that listing and trading of its listed securities on the NYSE will end at market close on March 20, 2023. The Class A ordinary shares and warrants of the post-business combination company, to be renamed Zura Bio Limited., are anticipated to begin trading on Nasdaq at market open on March 21, 2023 under the ticker symbols “ZURA” and “ZURAW.”\n\nIn compliance with NYSE’s Listing Rules, the Company provided NYSE with notice of its intent to delist its Class A ordinary shares and public warrants from the NYSE on March 10, 2023. The Nasdaq listing and NYSE delisting are subject to the closing of the Business Combination and fulfillment of all Nasdaq listing requirements.\n\nImportant Information\n\nNeither the SEC nor any state securities commission has approved or disapproved of the securities to be issued in connection with the Business Combination, or determined if the Registration Statement is accurate or adequate.\n\nAbout Zura Bio Limited\n\nZura is a clinical-stage biotechnology company advancing two primary assets, ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease (COPD) and asthma. ZB-168 is an anti IL7Rα inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in Alopecia Areata. This will build on Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at Phase 2 clinical development stage. IL33 ...